Published in Biomatter on January 01, 2014
Modeling pancreatic cancer with organoids. Trends Cancer (2016) 0.79
Poly(vinyl alcohol)/gelatin Hydrogels Cultured with HepG2 Cells as a 3D Model of Hepatocellular Carcinoma: A Morphological Study. J Funct Biomater (2015) 0.77
Microenvironment complexity and matrix stiffness regulate breast cancer cell activity in a 3D in vitro model. Sci Rep (2016) 0.75
Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Sci Rep (2017) 0.75
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 13.41
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
Pancreatic cancer. Lancet (2011) 8.54
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res (2003) 3.30
Scaffold design and fabrication technologies for engineering tissues--state of the art and future perspectives. J Biomater Sci Polym Ed (2001) 2.56
Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol (2005) 2.26
Three-dimensional scaffolds for tissue engineering applications: role of porosity and pore size. Tissue Eng Part B Rev (2013) 1.60
The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat (2010) 1.55
Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer (2000) 1.39
Tissue engineering and developmental biology: going biomimetic. Tissue Eng (2006) 1.34
Can tissue engineering concepts advance tumor biology research? Trends Biotechnol (2010) 1.32
3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing. BMC Cancer (2013) 1.31
Translating tissue engineering technology platforms into cancer research. J Cell Mol Med (2009) 1.29
Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol (2003) 1.22
Engineering tumors: a tissue engineering perspective in cancer biology. Tissue Eng Part B Rev (2010) 1.19
Fiber diameter and texture of electrospun PEOT/PBT scaffolds influence human mesenchymal stem cell proliferation and morphology, and the release of incorporated compounds. Biomaterials (2006) 1.15
Tumor engineering: the other face of tissue engineering. Tissue Eng Part A (2010) 1.12
Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics. Neoplasia (2013) 1.11
High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One (2012) 1.02
Current knowledge on pancreatic cancer. Front Oncol (2012) 1.01
A phenotypic comparison of osteoblast cell lines versus human primary osteoblasts for biomaterials testing. J Biomed Mater Res A (2013) 0.96
Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-κB Axis that induces expression of MMP9 and uPA in human pancreas progenitor cells. PLoS One (2013) 0.96
Advancements in electrospinning of polymeric nanofibrous scaffolds for tissue engineering. Tissue Eng Part B Rev (2013) 0.88
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. Lab Invest (2008) 0.84
Microengineered tumor models: insights & opportunities from a physical sciences-oncology perspective. Biomed Microdevices (2013) 0.84
Engineering fibrotic tissue in pancreatic cancer: a novel three-dimensional model to investigate nanoparticle delivery. Biochem Biophys Res Commun (2012) 0.84
[New insights into the origin of pancreatic cancer. Role of atypical flat lesions in pancreatic carcinogenesis]. Pathologe (2012) 0.83
Biomaterial scaffolds for tissue engineering. Front Biosci (Elite Ed) (2013) 0.83
Molecular markers in pancreatic cancer diagnosis. Clin Chim Acta (2013) 0.83
Biomimetic calcium phosphate coatings on Polyactive 1000/70/30. J Biomed Mater Res (2002) 0.82
Prognostic significance of extracellular matrix degrading enzymes-cathepsin L and matrix metalloproteases-2 [MMP-2] in human pancreatic cancer. Cancer Invest (2013) 0.81
A tissue-engineered subcutaneous pancreatic cancer model for antitumor drug evaluation. Int J Nanomedicine (2013) 0.80
The regulation of expanded human nasal chondrocyte re-differentiation capacity by substrate composition and gas plasma surface modification. Biomaterials (2005) 0.80
Loss of heterozygosity status of D9S105 marker is associated with downregulation of Krüppel-like factor 4 expression in pancreatic ductal adenocarcinoma and pancreatic intraepithelial lesions. Pancreatology (2011) 0.79
Interaction of human gingival fibroblasts with PVA/gelatine sponges. Micron (2007) 0.79
Ukrain affects pancreas cancer cell phenotype in vitro by targeting MMP-9 and intra-/extracellular SPARC expression. Pancreatology (2010) 0.79
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs. J Biotechnol (2013) 0.78
A clinical feasibility study to evaluate the safety and efficacy of PEOT/PBT implants for human donor site filling during mosaicplasty. Eur J Orthop Surg Traumatol (2011) 0.78
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes (2005) 2.47
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res (2006) 2.38
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res (2010) 2.22
Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case-control study. Am J Gastroenterol (2013) 2.11
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One (2010) 1.96
Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother (2012) 1.87
Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1.69
Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol (2009) 1.68
Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab (2004) 1.66
Control of immune response by amino acid metabolism. Immunol Rev (2010) 1.63
Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe (2013) 1.62
Part I: Vaccines for solid tumours. Lancet Oncol (2004) 1.61
Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep (2012) 1.59
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood (2005) 1.56
Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev (2007) 1.55
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood (2011) 1.47
Differential response of adult and embryonic mesenchymal progenitor cells to mechanical compression in hydrogels. Stem Cells (2007) 1.42
Death of healthy volunteers and professionals on duty for cadaveric graft shipment. Transplantation (2011) 1.38
Human gyrovirus DNA in human blood, Italy. Emerg Infect Dis (2012) 1.36
Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes (2002) 1.34
Role of arginine metabolism in immunity and immunopathology. Immunobiology (2007) 1.33
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31
Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res (2005) 1.28
Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol (2011) 1.25
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood (2009) 1.20
Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev (2007) 1.19
Endothelial differentiation of mesenchymal stromal cells. PLoS One (2012) 1.14
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol (2006) 1.11
Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care (2005) 1.09
Cationic polymers and their therapeutic potential. Chem Soc Rev (2012) 1.08
Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol (2014) 1.08
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 1.07
miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity (2013) 1.07
Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol (2011) 1.07
Insulin secretory function is impaired in isolated human islets carrying the Gly(972)-->Arg IRS-1 polymorphism. Diabetes (2002) 1.07
Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery (2009) 1.06
Effects of pancreas-kidney transplantation on diabetic retinopathy. Transpl Int (2005) 1.06
The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets. Eur J Endocrinol (2006) 1.04
Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med (2012) 1.04
Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol (2011) 1.03
The pancreatic beta cells in human type 2 diabetes. Adv Exp Med Biol (2012) 1.02
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine (2010) 1.02
Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol (2011) 1.02
High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One (2012) 1.02
The beta-cell in human type 2 diabetes. Adv Exp Med Biol (2010) 1.01
Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev (2011) 1.01
Enhancement of neurite outgrowth in neuronal-like cells following boron nitride nanotube-mediated stimulation. ACS Nano (2010) 1.01
Retracted High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res (2012) 1.01
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res (2009) 1.00
Isolation and clonal analysis of human epidermal keratinocyte stem cells in long-term culture. Stem Cells (2003) 0.99
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res (2008) 0.99
The pros and cons of chemokines in tumor immunology. Trends Immunol (2012) 0.99
Chitosan/poly(epsilon-caprolactone) blend scaffolds for cartilage repair. Biomaterials (2010) 0.98
KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. Am J Pathol (2010) 0.98
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther (2012) 0.98
Cancer vaccines: pessimism in check. Nat Med (2004) 0.97
Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin Cancer Biol (2007) 0.97
Are we overestimating the loss of beta cells in type 2 diabetes? Diabetologia (2014) 0.96